Krakow, Poland – 20 August 2019 – Selvita and Sandoz researchers have recently jointly published an article: Mini-Review: The Chemistry of Vorapaxar – Is There Any Room for Improvement Left?, which appeared in the Heterocycles, an International Journal for Reviews and Communications in Heterocyclic Chemistry, published online by The Japan Institute…
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Krakow, Poland – 25 July 2019 – Selvita, S.A. (WSE: SLV), a leading clinical stage drug discovery company committed to developing innovative medicines for treatment of patients with cancer, announced today the appointment of Setareh Shamsili, M.D., Ph.D., to the role of Chief Medical Officer. A seasoned veteran, Dr. Shamsili…
Selvita to exhibit at the 20th Annual Drug Discovery Summit 2019 conference
Krakow, Poland – 5 June 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will exhibit at the upcoming 20th Annual Drug Discovery Summit, taking place on June 11-12, in Berlin, Germany. Throughout the whole event, Selvita’s team will be available at booth #8….
Selvita present at the EFMC-ACSMEDI MedChem Frontiers 2019 Conference
Krakow, Poland – 3 June 2019 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and development partner for the pharmaceutical and biotechnology industries, will present at the upcoming EFMC-ACSMEDI MedChem Frontiers 2019 Conference, taking place June 10-13, in Krakow. Throughout…
Selvita at the Annual BIO International Convention 2019
Krakow, Poland – 28 May 2019 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services will be present at the BIO International Convention, taking place on June 3-6 in Philadelphia, PA, USA. BIO International Convention…
Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update
– Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S. Food and Drug Administration (FDA) – – Dosing of first patient in Phase 1 study of SEL120 expected in the third quarter of 2019 – – Split of oncology therapeutics…